Windward Bio raised $165 million to advance a China-derived long-acting TSLP drug into Phase 3 trials for asthma.
The funding supports ambitions in long-acting TSLP therapeutics.
News reported across biotech outlets like Brutalist Bio and Endpoints, highlighting a trend of small teams with big funding for Chinese biotech assets.
Articles published within the last 14 hours as of recent updates.